Studies on the Functionality of Newly Synthesized Fibrinogen after Treatment of Acute Myocardial Infarction with Streptokinase, Increase in the Rate of Fibrinopeptide Release

Edelmiro Regano; Virtudes Vila; Justo Aznar; Victoria Lacueva; Vicenta Martinez; Miguel Ruano

doi:10.1055/s-0038-1649710

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1993; 70(06): 0978-0983
DOI: 10.1055/s-0038-1649710

Original Article

Fibrinolysis

Schattauer GmbH Stuttgart

Studies on the Functionality of Newly Synthesized Fibrinogen after Treatment of Acute Myocardial Infarction with Streptokinase, Increase in the Rate of Fibrinopeptide Release

Edelmiro Regano

¹The Research Center, University Hospital La Fe, Valencia, Spain

,

Virtudes Vila

¹The Research Center, University Hospital La Fe, Valencia, Spain

,

Justo Aznar

²The Department of Clinical Pathology, University Hospital La Fe, Valencia, Spain

,

Victoria Lacueva

³The Intensive Care Unit, University Hospital La Fe, Valencia, Spain

,

Vicenta Martinez

¹The Research Center, University Hospital La Fe, Valencia, Spain

,

Miguel Ruano

³The Intensive Care Unit, University Hospital La Fe, Valencia, Spain

› Institutsangaben

Abstract

als PDF herunterladen

Summary

In 15 patients with acute myocardial infarction who received 1,500,000 U of streptokinase, the gradual appearance of newly synthesized fibrinogen and the fibrinopeptide release during the first 35 h after SK treatment were evaluated. At 5 h the fibrinogen circulating in plasma was observed as the high molecular weight fraction (HMW-Fg). The concentration of HMW-Fg increased continuously, and at 20 h reached values higher than those obtained from normal plasma. HMW-Fg represented about 95% of the total fibrinogen during the first 35 h. The degree of phosphorylation of patient fibrinogen increased from 30% before treatment to 65% during the first 5 h, and then slowly declined to 50% at 35 h.

The early rates of fibrinopeptide A (FPA) and phosphorylated fibrinopeptide A (FPAp) release are higher in patient fibrinogen than in isolated normal HMW-Fg and normal fibrinogen after thrombin addition. The early rate of fibrinopeptide B (FPB) release is the same for the three fibrinogen groups. However, the late rate of FPB release is higher in patient fibrinogen than in normal HMW-Fg and normal fibrinogen. Therefore, the newly synthesized fibrinogen clots faster than fibrinogen in the normal steady state.

In two of the 15 patients who had occluded coronary arteries after SK treatment the HMW-Fg and FPAp levels increased as compared with the 13 patients who had patent coronary arteries.

These results provide some support for the idea that an increased synthesis of fibrinogen in circulation may result in a procoagulant tendency. If this is so, the HMW-Fg and FPAp content may serve as a risk index for thrombosis.

PDF (1190 kb)

Referenzen

References
1 ISAM Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM). Mortality, morbidity, and infarct size at 21 days. New Engl J Med 1986; 314: 1465-1471
2 Gruppo Italiano per lo Studio della Streptochinasi nell’infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-402
3 ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-360
4 Sherry S. Appraisal of various thrombolytic agents in the treatment of acute myocardial infarction. Am J Med 1987; 83: 31-46
5 Marder VJ, Sherry S. Thrombolytic therapy: Current status. N Engl J Med 1988; 318: 1512-1520
6 Meade TW, Chakrabarti R, Haines AP, North WRS, Stirling Y, Thompson SG. Haemostatic function and cardiovascular death: Early results of a prospective study. Lancet 1980; 1: 1050-1054
7 Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as risk factor for stroke and myocardial infarction. N Engl J Med 1984; 311: 501-505
8 Kannel WB, Wolf PA, Catelli WP, D’Agostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham study. JAMA 1987; 258: 1183-1186
9 Lee AJ, Smith WCS, Lowe GDO, Tunstall-Peodoe H. Plasma fibrinogen and coronary risk factors. The Scottish Heart Health Study. J Clin Epidemiol 1990; 43: 913-919
10 Poliak H, Fischer M, Fritsch S, Enenkel W. Are admission plasma fibrinogen levels useful in the characterization of risk groups after myocardial infarction treated with fibrinolysis. Thromb Haemostas 1991; 66: 406-409
11 Vila V, Reganon E, Aznar J, Lacueva V, Ruano M, Laiz B. Hypercoagulable state after thrombolytic therapy in patients with acute myocardial infarction (AMI) treated with streptokinase. Thromb Res 1990; 57: 783-794
12 Seifried E, Oethinger M, Tanswell H, Hoegee-de NobelH, Nieuwenhuizen W. Studies on the functionality of fibrinogen during rt-PA therapy: results of three different methods of fibrinogen determination. Blood Coagulation and Fibrinolysis 1992; 3: 81-87
13 Ritchie DG, Levy BA, Adams MA, Fuller GM. Regulation of fibrinogen synthesis by plasmin-derived fragments of fibrinogen and fibrin. An indirect feedback pathway. Proc Nat Acad Sci USA 1982; 79: 1530-1534
14 Princen HMG, Moshage HJ, Emeis JJ, de HaardHJW, Nieuwenhuizen W, Yap SH. Fibrinogen fragments X, Y, D and E increase levels of plasma fibrinogen and liver mRNAs coding for fibrinogen polypeptides in rats. Thromb Haemostas 1985; 53: 212-215
15 Koj A. Acute phase reactants: their synthesis, turnover and biological significance. In: Structure and function of plasma proteins. Allison AC. ed. New York: Plenum Press; 1974: 073-131
16 Cristal N, Slomin A, Bar-Ilan I, Hart A. Plasma fibrinogen levels and the clinical course of acute myocardial infarction. Angiology 1983; 11: 693-698
17 Holm B, Godal HC. Quantitation of the three normal occurring plasma fibrinogens in health and during so-called “acute phase” by SDS-electrophoresis of fibrin obtained from EDTA-plasma. Thromb Res 1984; 35: 279-290
18 Seydewitz HH, Witt I. The fraction of high molecular weight (HMW) fibrinogen and phosphorylated fibrinopeptide A in fetal fibrinogen. Thromb Res 1989; 55: 785-790
19 Lipinska J, Lipinski B, Gurewich V. Fibrinogen heterogeneity in human plasma. Electrophoretic demonstration and characterization of two major components. J Lab Clin Med 1974; 84: 509-516
20 Holm B, Godal HC. Quantitation of the three normal occurring plasma fibrinogens in health and during so-called “acute phase” by SDS-electrophoresis of fibrin obtained from EDTA-plasma. Thromb Res 1984; 35: 179-290
21 Reganon E, Vila V, Aznar J, Garrido G, Estelles A, Berenguer J. Study of formation of fibrin clot in cirrhotic patients. An approach to study of acquired dysfibrinogenemia. Thromb Res 1987; 46: 705-715
22 Mosesson MW, Alkjaersig N, Sweet B, Sherry S. Human fibrinogen of relatively high solubility. Comparative Biophysical, Biochemical and Biological studies with fibrinogen of lower solubility. Biochemistry 1967; 6: 3279-3287
23 Holm JB, Nilsen DWT, Kierulf P, Godal HC. Purification and characterization of 3 fibrinogens with different molecular weight obtained from human plasma. Thromb Res 1985; 37: 165-176
24 Reganon E, Vila V, Aznar J, Laiz B. Human fibrinogen heterogeneity. A study of limited fibrinogen degradation. Clin Chim Acta 1989; 184: 07-18
25 Hasegawa N, Sasaki S. Localization of the binding site “b” for lateral polymerization of fibrin. Thromb Res 1990; 57: 183-195
26 Seydewitz HH, Matthias FR, Schondorf TH, Witt I. Increase in the degree of phosphorylation of circulating fibrinogen under thrombolytic therapy with urokinase. Thromb Res 1987; 46: 437-445
27 Blomback B, Blomback M, Edman P, Hessel B. Human fibrinopeptides. Isolation, characterization and structure. Biochim Biophys Acta 1966; 115: 371-396
28 Seydewitz HH, Kaiser C, Rothweiler H, Witt I. The location of a second in vivo phosphorylation site in the Aa-chain of human fibrinogen. Thromb Res 1984; 33: 487-498
29 Seydewitz HH, Witt I. Increased phosphorylation of human fibrinopeptide A under acute phase conditions. Thromb Res 1985; 40: 29-39
30 Southan CH, Thompson E, Lane DA. Direct analysis of plasma fibrinogen-derived fibrinopeptides by high performance liquid chromatography: Investigation of Aα-chain N-terminal heterogeneity. Thromb Haemostas 1986; 56: 193-197
31 Southan CH, Lane DA. Screening small plasma samples by HPLC for abnormalities of fibrinopeptide release. In: Fibrinogen, fibrin formation and fibrinolysis. Lane DA, Henschen A, Jasani MK. eds. Berlin, New York: Walter de Gruyter; 1986: 111-118
32 Leeksma OC, Meijer-Huizinga FM, van MourikJA. Fibrinopeptide A and the phosphorylation of fibrinogen. In: Fibrinogen, fibrin formation and fibrinolysis. Lane DA, Henschen A, Jasani MK. eds. Berlin, New York: Walter de Gruyter; 1986: 23-31
33 Witt I, Hasler K. Influence of organically bound phosphorus in fetal and adult fibrinogen on the kinetics of interaction between thrombin and fibrinogen. Biochim Biophys Acta 1972; 271: 357-362
34 Kehl M, Lottspeich F, Henschen A. Analysis of human fibrinopeptides by high-performance liquid chromatography. Hoppe-Seyler’s Z Physiol Chem 1981; 362: 1661-1664
35 Hanna I, Scheraga HA, Francis CW, Marder VJ. Comparison of various human fibrinogens and a derivative thereof by a study of the kinetics of release of fibrinopeptides. Biochemistry 1984; 23: 4681-4687
36 Vila V, Reganon E, Lopis F, Aznar J. A rapid method for isolation of fibrinogen from human plasma by precipitation with polyethylene glycol 6000. Thromb Res 1985; 39: 651-656
37 Holm B, Nilsen DWT, Kierulf P, Godal HC. Purification and characterization of 3 fibrinogens with different molecular weights obtained from normal plasma. Thromb Res 1985; 37: 165-176
38 Laki K. The polymerization of proteins: The action of thrombin on fibrinogen. Arch Biochem Biophys 1951; 32: 317-324
39 Laemmli UK. Cleavage of structural protein during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685
40 Reganon E, Vila V, Aznar J. Gelification of fibrinogen in plasma. A kinetic study by turbidity measurement. Haemostasis 1984; 14: 170-178
41 Low EJ, Hill HB, Searly RL. Simple method for determination of normal plasma fibrinogen levels. Am J Clin Pathol 1967; 47: 538-548
42 Mihalyi E. Physicochemical studies of bovine fibrinogen IV. Ultraviolet absorption and its relation to the structure of the molecule. Biochemistry 1968; 7: 208-223
43 Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. Procedure and some application. Proc Natl Acad Sci USA 1979; 76: 4350-4354
44 Kehl M, Lottspeich F, Henschen A. Analysis of human fibrinopeptides by high-performance liquid chromatography. Hoppe-Seyler’s Z Physiol Chem 1981; 362: 1661-1664
45 Martinelli RA, Scheraga HA. Steady-state kinetic study of the bovine thrombin-fibrinogen interaction. Biochemistry 1980; 19: 2343-2350
46 Hurlet-Jensen A, Cummins HZ, Nossel HL, Liu CY. Fibrin polymerization and release of fibrinopeptide B by thrombin. Thromb Res 1982; 27: 419-427
47 Ferres H. Preclinical pharmacological evaluation of anisoylated streptokinase activator complex. Drugs 1987; 33: 33-50
48 Relik-van WelyL, Visser RF, van derPol JMJ, Bartholomeus I, Couvee JE, Drost H, Vet AJTM, Klomps HC, van EkelenWAAJ, van denBerg F, Krauss XH. Angiographically assessed coronary arterial patency and reocclusion in patients with acute myocardial infarction treated with anistreplase: Results of the anistreplase reocclusion multicenter study (ARMS). Am J Cardiol 1991; 68: 296-300